Wells Fargo initiated coverage on Repligen with a new price target

8/28/24 7:52:56 AM ET

Biotechnology: Biological Products (No Diagnostic Substances)

Health Care

Wells Fargo initiated coverage of Repligen with a rating of Overweight and set a new price target of $180.00

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$RGEN

Date	Price Target	Rating	Analyst
4/29/2025	$160.00	Peer Perform → Outperform	Wolfe Research
3/18/2025	$155.00	In-line	Evercore ISI
2/10/2025	$200.00	Buy	TD Cowen
12/17/2024	$165.00	Hold	Canaccord Genuity
11/14/2024		Peer Perform	Wolfe Research
8/28/2024	$180.00	Overweight	Wells Fargo
6/26/2024	$180.00 → $155.00	Hold → Buy	Deutsche Bank
6/18/2024		Neutral	Guggenheim